GT201600007A - Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos - Google Patents

Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos

Info

Publication number
GT201600007A
GT201600007A GT201600007A GT201600007A GT201600007A GT 201600007 A GT201600007 A GT 201600007A GT 201600007 A GT201600007 A GT 201600007A GT 201600007 A GT201600007 A GT 201600007A GT 201600007 A GT201600007 A GT 201600007A
Authority
GT
Guatemala
Prior art keywords
piperidinil
indol
inhibitors
derivatives
same
Prior art date
Application number
GT201600007A
Other languages
English (en)
Inventor
Christopher Adams
Michael Paul Capparelli
Takeru Ehara
Rajeshri Ganesh Karki
Nello Mainolfi
Chun Zhang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51230246&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201600007(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of GT201600007A publication Critical patent/GT201600007A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A LA INHIBICIÓN DE LA SENDA ALTERNATIVA DEL COMPLEMENTO Y EN PARTICULAR A LA INHIBICIÓN DEL FACTOR B, EN LOS PACIENTES QUE PADECEN DE CONDICIONES Y ENFERMEDADES ASOCIADAS CON LA ACTIVACIÓN DE LA SENDA ALTERNATIVA DEL COMPLEMENTO, TALES COMO DEGENERACIÓN MACULAR RELACIONADA CON LA EDAD, RETINOPATÍA DIABÉTICA Y ENFERMEDADES OFTÁLMICAS RELACIONADAS.
GT201600007A 2013-07-15 2016-01-14 Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos GT201600007A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361846355P 2013-07-15 2013-07-15
US201461977028P 2014-04-08 2014-04-08

Publications (1)

Publication Number Publication Date
GT201600007A true GT201600007A (es) 2018-12-18

Family

ID=51230246

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201600007A GT201600007A (es) 2013-07-15 2016-01-14 Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos

Country Status (40)

Country Link
US (2) US9682968B2 (es)
EP (2) EP3299365A1 (es)
JP (1) JP6378761B2 (es)
KR (1) KR102242742B1 (es)
CN (1) CN105579444B (es)
AP (1) AP2016008992A0 (es)
AU (1) AU2014290298B2 (es)
BR (1) BR112016000909B1 (es)
CA (1) CA2917839C (es)
CL (1) CL2016000060A1 (es)
CU (1) CU24397B1 (es)
CY (2) CY1119767T1 (es)
DK (1) DK3022192T3 (es)
EA (1) EA031030B1 (es)
ES (1) ES2655855T4 (es)
FI (1) FIC20240032I1 (es)
FR (1) FR24C1036I2 (es)
GT (1) GT201600007A (es)
HR (1) HRP20172000T1 (es)
HU (2) HUE037510T2 (es)
IL (2) IL243540B (es)
JO (1) JO3425B1 (es)
LT (2) LT3022192T (es)
MX (1) MX351291B (es)
MY (2) MY187454A (es)
NL (1) NL301292I2 (es)
NO (1) NO2024042I1 (es)
PE (1) PE20161066A1 (es)
PH (1) PH12016500072A1 (es)
PL (1) PL3022192T3 (es)
PT (1) PT3022192T (es)
RS (1) RS56721B1 (es)
SG (1) SG11201600086PA (es)
SI (1) SI3022192T1 (es)
SV (1) SV2016005137A (es)
TN (1) TN2016000017A1 (es)
TW (1) TWI641600B (es)
UA (1) UA117371C2 (es)
UY (1) UY35663A (es)
WO (1) WO2015009616A1 (es)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3425B1 (ar) 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
ES2908479T3 (es) 2015-08-26 2022-04-29 Achillion Pharmaceuticals Inc Compuestos para el tratamiento de trastornos inmunitarios e inflamatorios
US11332470B2 (en) * 2016-06-21 2022-05-17 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
JP7054529B2 (ja) 2016-06-21 2022-04-14 エックス４ ファーマシューティカルズ， インコーポレイテッド Ｃｘｃｒ４阻害剤およびその使用
EP3939591A1 (en) 2016-06-27 2022-01-19 Achillion Pharmaceuticals, Inc. Quinazoline and indole compounds to treat medical disorders
CN107641121B (zh) * 2016-07-20 2021-02-19 上海高驰资产管理有限公司 一种荧光探针及其制备方法和用途
AU2018227849B2 (en) 2017-03-01 2022-04-28 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
TWI847306B (zh) 2017-08-24 2024-07-01 丹麥商諾佛 儂迪克股份有限公司 Ｇｌｐ-１組成物及其用途
BR112020003737A2 (pt) 2017-08-31 2020-09-01 Novartis Ag usos de derivados de piperidinil-indol
CN112513025B (zh) * 2018-07-16 2025-03-25 诺华股份有限公司 用于制备苯基哌啶基吲哚衍生物的化学方法
JP7538113B2 (ja) 2018-08-20 2024-08-21 アキリオン ファーマシューティカルズ，インコーポレーテッド 補体ｄ因子の医学的障害の治療のための医薬化合物
EP3847174A4 (en) 2018-09-06 2022-06-15 Achillion Pharmaceuticals, Inc. MORPHIC FORMS OF COMPLEMENT D FACTOR INHIBITORS
WO2020051532A2 (en) 2018-09-06 2020-03-12 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
JP2022502500A (ja) 2018-09-25 2022-01-11 アキリオン ファーマシューティカルズ， インコーポレーテッド 補体因子ｄ阻害剤の形態
CA3125886A1 (en) 2019-01-11 2020-07-16 Novartis Ag Anti-cd40 antibodies for use in treatment of hidradenitis suppurativa
KR102630669B1 (ko) 2019-01-11 2024-01-30 노파르티스 아게 화농성 한선염 치료를 위한 lta4h 억제제
BR112022013795A2 (pt) 2020-02-18 2022-09-13 Novo Nordisk As Composição farmacêutica líquida, e, kit
CN115362162A (zh) 2020-02-20 2022-11-18 艾其林医药公司 用于治疗补体因子d介导的障碍的杂芳基化合物
WO2021234544A1 (en) * 2020-05-18 2021-11-25 Novartis Ag Crystalline form of lnp023
WO2022013604A1 (en) 2020-07-16 2022-01-20 Novartis Ag Methods of using factor b inhibitors
US11951101B2 (en) 2020-07-16 2024-04-09 Novartis Ag Methods of using factor B inhibitors
WO2022028527A1 (zh) * 2020-08-07 2022-02-10 上海美悦生物科技发展有限公司 补体因子b抑制剂及其药物组合物、制备方法和用途
WO2022028507A1 (zh) * 2020-08-07 2022-02-10 上海美悦生物科技发展有限公司 一种杂环类化合物、其制备方法及用途
JP7787164B2 (ja) 2020-09-23 2025-12-16 アキリオン ファーマシューティカルズ， インコーポレーテッド 補体媒介性障害の治療のための医薬化合物
CN116583508B (zh) * 2020-12-30 2025-05-23 浙江星浩澎博医药有限公司 一系列哌啶取代的苯酸类化合物及其应用
MX2023007853A (es) * 2020-12-30 2023-07-07 Jiangsu Hengrui Pharmaceuticals Co Ltd Compuesto heterociclico puenteado que contiene nitrogeno, metodo de preparacion y uso medico del mismo.
CN116848238A (zh) * 2021-01-14 2023-10-03 阿雷克森制药公司 大环补体因子b抑制剂
CA3214014A1 (en) * 2021-04-16 2022-10-20 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Bicyclic substituted aromatic carboxylic acid compounds
MX2023013148A (es) * 2021-05-07 2023-11-28 Novartis Ag Iptacopan para el tratamiento del sindrome uremico hemolitico atipico.
KR20240017004A (ko) * 2021-06-03 2024-02-06 치누크 세라퓨틱스, 인크. 치환된 인돌 화합물 및 이의 사용 방법
US20240277689A1 (en) 2021-06-18 2024-08-22 Novartis Ag Method of treating an autoimmune hematological disorder
EP4362933A4 (en) * 2021-06-30 2025-06-04 Apellis Pharmaceuticals, Inc. COMPLEMENT INHIBITION
JP2024532847A (ja) * 2021-08-18 2024-09-10 シーザン ハイスーク ファーマシューティカル カンパニー リミテッド ベンズアゼピン芳香環誘導体及びその医薬的な応用
WO2023037218A1 (en) 2021-09-07 2023-03-16 Novartis Ag Use of factor b inhibitors for the treatment of age-related macular degeneration
CA3236104A1 (en) * 2021-10-27 2023-05-04 Hugh Y. Zhu Piperidinyl indole derivatives, preparation methods and medicinal uses thereof
PE20242005A1 (es) 2022-01-24 2024-10-03 Novartis Ag Derivados espirociclicos de piperidinilo como inhibidores del factor b del complemento y usos de los mismos
EP4471021A4 (en) * 2022-01-26 2025-04-30 Shanghai Meiyue Biotech Development Co., Ltd. Salt type and crystal form of complement factor b inhibitor, and preparation method therefor and application thereof
TW202342048A (zh) 2022-02-28 2023-11-01 瑞士商諾華公司 使用ｌｏｕ０６４治療化膿性汗腺炎之方法
AU2023229221A1 (en) 2022-03-04 2024-08-15 Novartis Ag Use of iptacopan for the treatment of lupus nephritis
US20250223277A1 (en) 2022-04-01 2025-07-10 Novartis Ag Complement factor b inhibitors and uses thereof
WO2023246677A1 (zh) * 2022-06-20 2023-12-28 深圳信立泰药业股份有限公司 一种吲哚-苯基哌啶化合物及其制备方法与应用
WO2023246870A1 (zh) * 2022-06-23 2023-12-28 上海济煜医药科技有限公司 吲哚化合物的制备、应用及用途
WO2024002353A1 (zh) 2022-06-30 2024-01-04 江苏恒瑞医药股份有限公司 一种含氮桥杂环衍生物的可药用盐、晶型及其制备方法
AU2023335519A1 (en) * 2022-08-29 2025-04-03 Cms Research & Development Pte. Ltd. Series of nitrogen-containing bridged heterocyclic compounds and preparation method therefor
TW202423426A (zh) * 2022-08-31 2024-06-16 美商奇努克醫療股份有限公司 經取代之吲哚化合物及其使用方法
CA3266935A1 (en) 2022-09-10 2024-03-14 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Piperidine derivatives substituted at position 2, their preparation methods and medicinal uses
CN118026998A (zh) 2022-11-11 2024-05-14 上海医药工业研究院有限公司 哌啶取代的苯甲酸类化合物、其药物组合物和应用
WO2024104292A1 (en) * 2022-11-14 2024-05-23 Novartis Pharma Ag Solid forms of complement factor b inhibitors
WO2024114677A1 (zh) * 2022-11-29 2024-06-06 上海济煜医药科技有限公司 苯并螺环吲哚化合物的制备、应用及用途
WO2024141011A1 (zh) * 2022-12-31 2024-07-04 深圳晶泰科技有限公司 补体因子b抑制剂及其药物组合物和应用
WO2024148274A1 (en) * 2023-01-05 2024-07-11 Apellis Pharmaceuticals, Inc. Complement inhibition
TW202434240A (zh) 2023-02-22 2024-09-01 大陸商西藏海思科製藥有限公司 苯並氮雜芳環衍生物的藥物組合物及其在醫藥上的應用
EP4669321A1 (en) 2023-02-23 2025-12-31 Novartis AG METHODS OF USING FACTOR B INHIBITORS
WO2024193575A1 (zh) * 2023-03-21 2024-09-26 上海美悦生物科技发展有限公司 螺环类化合物及其药物组合物、制备方法和用途
EP4703356A1 (en) 2023-04-27 2026-03-04 Shanghai Hansoh Biomedical Co., Ltd. Salt of piperidylindole compound and preparation method therefor
WO2025008453A1 (en) 2023-07-04 2025-01-09 Sitala Bio Ltd 2-(1h-indol-4-yl)methyl)-isoindoline derivatives as factor b inhibitors
AU2024291322A1 (en) 2023-07-04 2026-02-19 Sitala Bio Ltd 2-(1h-indol-4-yl)methyl)2h-indazole derivatives as factor b inhibitors
WO2025008516A2 (en) 2023-07-06 2025-01-09 Sitala Bio Ltd Novel compounds
WO2025008517A1 (en) 2023-07-06 2025-01-09 Sitala Bio Ltd Indole derivatives with factor b inhibitory activity
CN119371402A (zh) 2023-07-26 2025-01-28 上海美悦生物科技发展有限公司 螺环烯基类或氮杂烯基类化合物及其药物组合物、制备方法和用途
WO2025046421A1 (en) 2023-08-25 2025-03-06 Novartis Ag Methods of using factor b inhibitors
TW202515541A (zh) 2023-09-29 2025-04-16 瑞士商諾華公司 補體因子ｂ抑制劑及其用途
WO2025083621A1 (en) 2023-10-20 2025-04-24 Novartis Ag Treatment of hidradenitis suppurativa using anti-baff-r antibodies
WO2025119266A1 (zh) * 2023-12-05 2025-06-12 西藏海思科制药有限公司 苯并氮杂芳环衍生物在治疗补体因子b介导的疾病中的用途
WO2025148628A1 (zh) * 2024-01-10 2025-07-17 河北以岭医药研究院有限公司 哌啶基吲哚衍生物及其制备方法和应用
WO2025172535A1 (en) 2024-02-15 2025-08-21 Sitala Bio Ltd Indole and benzimidazole compounds as factor b inhibitors
TW202533829A (zh) 2024-02-16 2025-09-01 瑞士商諾華公司 用於治療anca相關性血管炎的因子b抑制劑
WO2025185734A1 (zh) * 2024-03-08 2025-09-12 江苏豪森药业集团有限公司 一种多元螺环化合物的盐及其晶型、其制备方法和医药用途
CN121532400A (zh) * 2024-05-11 2026-02-13 礼邦医药(香港)有限公司 补体因子b抑制剂
WO2025252133A1 (zh) * 2024-06-07 2025-12-11 润尔眼科药物（广州）有限公司 一种含吲哚基团的化合物及其用途
WO2025256647A1 (zh) * 2024-06-14 2025-12-18 润尔眼科药物（广州）有限公司 化合物及其医药用途
WO2026002007A1 (zh) * 2024-06-25 2026-01-02 珠海联邦制药股份有限公司 补体因子b抑制剂及其药物组合物和应用
WO2026003809A1 (en) * 2024-06-29 2026-01-02 Assia Chemical Industries Ltd. Solid state forms of iptacopan hydrochloride
WO2026008074A1 (zh) * 2024-07-05 2026-01-08 南京正大天晴制药有限公司 补体因子b抑制剂的晶型、其制备方法及用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR030357A1 (es) 2000-08-18 2003-08-20 Lundbeck & Co As H Derivados 4 -, 5 -, 6 - y 7-indol
DE10217006A1 (de) * 2002-04-16 2003-11-06 Merck Patent Gmbh Substituierte Indole
DE10237723A1 (de) 2002-08-17 2004-07-08 Aventis Pharma Deutschland Gmbh Verwendung von IKappaB-Kinase Inhibitoren in der Schmerztherapie
PL377713A1 (pl) 2002-12-19 2006-02-06 Pfizer Inc. Związki 2-(1H-indazol-6-iloamino)benzamidowe jako inhibitory kinaz białkowych użyteczne w leczeniu chorób oczu
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
MXPA05011536A (es) 2003-04-30 2006-01-23 Inst For Pharm Discovery Inc Acidos carboxilicos substituidos con fenilo como inhibidores de la proteina tirosina fosfatasa-1b.
CA2587566A1 (en) 2004-11-18 2006-05-26 The Institutes For Pharmaceutical Discovery, Llc Heterocyclylbiphenyl derivates as protein tyrosine phosphatase inhibitors
AU2006212951A1 (en) * 2005-02-08 2006-08-17 Merck & Co., Inc. Inhibitors of checkpoint kinases
WO2009042092A1 (en) 2007-09-25 2009-04-02 Merck & Co., Inc. 2-aryl or heteroaryl indole derivatives
WO2009076404A1 (en) 2007-12-10 2009-06-18 Epix Delaware, Inc. Carboxamide compounds and their use as antagonists of the chemokine ccr2 receptor
AR070398A1 (es) 2008-02-22 2010-03-31 Gruenenthal Chemie Derivados sustituidos de indol
JO3265B1 (ar) 2008-12-09 2018-09-16 Novartis Ag مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
WO2011006794A1 (en) 2009-07-14 2011-01-20 Nerviano Medical Sciences S.R.L. 3-oxo-2, 3-dihydro-lh-isoindole-4-carboxamides as parp inhibitors
EP3064204A1 (en) 2010-03-01 2016-09-07 GTx, Inc. Compounds for treatment of cancer
WO2012068589A2 (en) 2010-11-19 2012-05-24 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
WO2012093101A1 (en) * 2011-01-04 2012-07-12 Novartis Ag Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd)
PT2855456T (pt) * 2012-05-04 2017-07-10 Novartis Ag Moduladores da via do complemento e usos dos mesmos
EA201590053A1 (ru) * 2012-06-20 2015-08-31 Новартис Аг Модуляторы пути системы комплемента и их применение
JO3425B1 (ar) 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b

Also Published As

Publication number Publication date
IL243540A0 (en) 2016-02-29
UA117371C2 (uk) 2018-07-25
CY1119767T1 (el) 2018-06-27
FR24C1036I1 (fr) 2024-12-06
PH12016500072B1 (en) 2016-04-18
CA2917839A1 (en) 2015-01-22
DK3022192T3 (en) 2018-01-22
EA031030B1 (ru) 2018-11-30
PT3022192T (pt) 2018-01-15
PE20161066A1 (es) 2016-10-30
EA201690223A1 (ru) 2016-06-30
NL301292I2 (nl) 2024-10-30
US20160152605A1 (en) 2016-06-02
HK1221217A1 (en) 2017-05-26
IL243540B (en) 2019-09-26
US10093663B2 (en) 2018-10-09
CY2024027I2 (el) 2025-09-26
HRP20172000T1 (hr) 2018-02-09
WO2015009616A1 (en) 2015-01-22
EP3299365A1 (en) 2018-03-28
UY35663A (es) 2015-02-27
CN105579444B (zh) 2018-05-01
AP2016008992A0 (en) 2016-01-31
CU20160006A7 (es) 2016-08-31
US20180009795A1 (en) 2018-01-11
KR102242742B1 (ko) 2021-04-23
CL2016000060A1 (es) 2016-06-10
EP3022192B1 (en) 2017-10-11
SV2016005137A (es) 2018-06-12
FIC20240032I1 (fi) 2024-10-01
RS56721B1 (sr) 2018-03-30
IL268623B (en) 2020-01-30
CA2917839C (en) 2022-05-03
PL3022192T3 (pl) 2018-03-30
BR112016000909A8 (pt) 2020-01-07
KR20160030556A (ko) 2016-03-18
PH12016500072A1 (en) 2016-04-18
SG11201600086PA (en) 2016-02-26
LTPA2024526I1 (es) 2024-10-10
CU24397B1 (es) 2019-04-04
ES2655855T4 (es) 2024-09-06
NZ715780A (en) 2021-03-26
MY196427A (en) 2023-04-10
MY187454A (en) 2021-09-22
MX351291B (es) 2017-10-09
ES2655855T3 (es) 2018-02-21
BR112016000909A2 (pt) 2017-07-25
CN105579444A (zh) 2016-05-11
TWI641600B (zh) 2018-11-21
HUS2400034I1 (hu) 2024-10-28
IL268623A (en) 2019-10-31
NO2024042I1 (no) 2024-09-30
JP6378761B2 (ja) 2018-08-22
AU2014290298A1 (en) 2016-02-11
US9682968B2 (en) 2017-06-20
LT3022192T (lt) 2017-12-27
CY2024027I1 (el) 2025-09-26
TN2016000017A1 (en) 2017-07-05
EP3022192A1 (en) 2016-05-25
FR24C1036I2 (fr) 2025-08-01
AU2014290298B2 (en) 2017-06-15
SI3022192T1 (en) 2018-01-31
BR112016000909B1 (pt) 2023-05-02
JP2016526576A (ja) 2016-09-05
JO3425B1 (ar) 2019-10-20
HUE037510T2 (hu) 2018-09-28
TW201546058A (zh) 2015-12-16

Similar Documents

Publication Publication Date Title
GT201600007A (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
MX2016004340A (es) Compuestos heterociclicos y usos de los mismos.
DOP2015000246A (es) Derivados de oxopiridina sustituida y usos de los mismos en el tratamiento de trastornos cardiovasculares
MX2020001835A (es) Métodos para el tratamiento de retinopatía diabética y otras enfermedades oftálmicas.
AR091237A1 (es) Composiciones que comprenden un aptamero anti factor de crecimiento derivado de plaquetas (anti-pdgf) y un antagonista de factor de crecimiento de endotelio vascular (vegf)
MX370900B (es) Derivados del isocromeno como inhibidores de las fosfoinositido-3 cinasas.
CO7081142A2 (es) Métodos de tratamiento de enfermedades de degeneración retiniana
ECSP17013903A (es) Protein kinase c inhibitors and methods of their use
MX385585B (es) Anticuerpos anti-c10orf54 y usos de los mismos.
UY33883A (es) Novedosos derivados heterocíclicos
MX2017016376A (es) Derivado de piperidina y metodo de preparacion y uso farmaceutico del mismo.
CR20140476A (es) Agentes para tratar transtornos que implican la modulación de receptores de rianodina
CL2016000055A1 (es) Métodos para tratar o prevenir afecciones oftalmológicas
BR112017007123A2 (pt) derivados de tetrahidroisoquinolina
CL2017001301A1 (es) Composiciones oftálmicas estabilizadas de omega 3
CO2017005404A2 (es) Anticuerpos contra il-6
MX356052B (es) Terapias sinergicas de cannabidiol con hipotermia para neuroproteccion.
MX373129B (es) Derivados de indolizina como inhibidores de fosfoinositido-3 cinasas.
UY36171A (es) Derivados heteroaromáticos bicíclicos fusionados como inhibidores de quinasa
MX2016004378A (es) Sistema de diagnostico y metodo de diagnostico.
UY35439A (es) Formas salinas del (2-(2-(4-fluorofenil)tiazol-4-il)propan-2-il)carbamato de (S)-quinuclidin-3-ilo.
CR20160290A (es) Inhibidores tetracíclicos de autotaxina
UY35747A (es) Derivados sustituidos de fenilalanina
DOP2016000170A (es) Compuestos derivados de hidroxiformamida y usos del mismo
MX2015012444A (es) Metodos de diagnostico, seleccion y tratamiento de enfermedades y afecciones provocadas por o asociadas con metanogenos.